The incidence of<unk>  and<unk>  is approximately 1-5 per 100,000 individuals worldwide. The prevalence of<unk>  and<unk>  is approximately 5-22 per 100,000 individuals worldwide. The 5-year survival rate for<unk>  is 75% and for<unk>  is 63%. The median survival for<unk>  is 11.0 years and that for<unk>  is 12.3 years.<unk>  has a bimodal pattern, commonly affects both children and adults over 50 years old.<unk>  commonly affects adults after second decades of their lives and it is rare among children. There is no racial predilection to<unk>  and<unk> . The female to male ratio is approximately 2 to 1. Prevalence of<unk>  and<unk>  are lower in young rural men and higher in older urban women.
Polymyositis and dermatomyositis epidemiology and demographics
Polymyalgia rheumatica epidemiology and demographics
Sjögren's syndrome epidemiology and demographics
Polymyositis and dermatomyositis classification
Myasthenia gravis epidemiology and demographics
Diabetic neuropathy epidemiology and demographics
Statin induced myopathy epidemiology and demographics
Fibromyalgia epidemiology and demographics